Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bokemeyer

Showing results (271-280 of 333) with videos related to

Pageof 34
Sort By:
British Journal of Cancer|September 17, 2002
Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study GroupC Kollmannsberger, O Rick, H Klaproth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2004
Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancerO Rick, C Bokemeyer, S Weinknecht, et al.
Der Urologe. Ausg. A|July 1, 1998
[Prognostic relevance of vena cava thrombosis in renal cell carcinoma]M A Kuczyk, G Köhn, K Höfner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2004
Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study GroupC Kollmannsberger, J Beyer, R Liersch, et al.
ESMO Open|November 10, 2022
Effects of a communication training for oncologists on early addressing palliative and end-of-life care in advanced cancer care (PALLI-COM): a randomized, controlled trialN Harnischfeger, H M Rath, B Alt-Epping, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2002
Prognostic variables for response and outcome in patients with extragonadal germ-cell tumorsJ T Hartmann, C R Nichols, J-P Droz, et al.
Cancer|March 26, 1999
Treatment outcome of patients with brain metastases from malignant germ cell tumorsS D Fosså, C Bokemeyer, A Gerl, et al.
Oncoimmunology|July 2, 2021
Increased frequency of TIGIT<sup>+</sup>CD73-CD8<sup>+</sup> T cells with a TOX<sup>+</sup> TCF-1low profile in patients with newly diagnosed and relapsed AMLF Brauneck, F Haag, R Woost, et al.
Bone Marrow Transplantation|April 4, 2000
Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infectionH Einsele, H Hebart, C Kauffmann-Schneider, et al.
Cancer|June 22, 2000
The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumorsJ T Hartmann, C R Nichols, J P Droz, et al.
Pageof 34

Showing results (271-280 of 333) with videos related to

Sort By:
Pageof 34
British Journal of Cancer|September 17, 2002
Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study GroupC Kollmannsberger, O Rick, H Klaproth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2004
Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancerO Rick, C Bokemeyer, S Weinknecht, et al.
Der Urologe. Ausg. A|July 1, 1998
[Prognostic relevance of vena cava thrombosis in renal cell carcinoma]M A Kuczyk, G Köhn, K Höfner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2004
Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study GroupC Kollmannsberger, J Beyer, R Liersch, et al.
ESMO Open|November 10, 2022
Effects of a communication training for oncologists on early addressing palliative and end-of-life care in advanced cancer care (PALLI-COM): a randomized, controlled trialN Harnischfeger, H M Rath, B Alt-Epping, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2002
Prognostic variables for response and outcome in patients with extragonadal germ-cell tumorsJ T Hartmann, C R Nichols, J-P Droz, et al.
Cancer|March 26, 1999
Treatment outcome of patients with brain metastases from malignant germ cell tumorsS D Fosså, C Bokemeyer, A Gerl, et al.
Oncoimmunology|July 2, 2021
Increased frequency of TIGIT<sup>+</sup>CD73-CD8<sup>+</sup> T cells with a TOX<sup>+</sup> TCF-1low profile in patients with newly diagnosed and relapsed AMLF Brauneck, F Haag, R Woost, et al.
Bone Marrow Transplantation|April 4, 2000
Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infectionH Einsele, H Hebart, C Kauffmann-Schneider, et al.
Cancer|June 22, 2000
The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumorsJ T Hartmann, C R Nichols, J P Droz, et al.
Pageof 34